CYP3A4*22 Genotype-Guided Dosing of Kinase Inhibitors in Cancer Patients

INTRODUCTION: A genetic variant explaining a part of the exposure of many kinase inhibitors (KIs) is the single nucleotide polymorphism (SNP) CYP3A4*22, resulting in less CYP3A4 enzyme activity. The primary aim of this study was to investigate if the systemic exposure is non-inferior after a dose re...

Descripción completa

Detalles Bibliográficos
Autores principales: van Eerden, Ruben A. G., IJzerman, Nikki S., van Meekeren, Milan, Oomen-de Hoop, Esther, Guchelaar, Niels A. D., Visser, Andrea M. W., Matic, Maja, van Schaik, Ron H. N., de Bruijn, Peter, Moes, Dirk-Jan A. R., Jobse, Pieter A., Gelderblom, Hans, Huitema, Alwin D. R., Steeghs, Neeltje, Mathijssen, Ron H. J., Koolen, Stijn L. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386914/
https://www.ncbi.nlm.nih.gov/pubmed/37310647
http://dx.doi.org/10.1007/s40262-023-01260-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386914/
https://www.ncbi.nlm.nih.gov/pubmed/37310647
http://dx.doi.org/10.1007/s40262-023-01260-4

Ejemplares similares